Key Highlights
- The first patient commercially treated with the OncoSilTM device at Memorial Hospital in Istanbul, Türkiye has undergone a successful resection of the primary tumour.
- This milestone supports the global expansion of OncoSil™, showcasing its effectiveness in a new international market. OncoSil is actively collaborating with several additional institutions in Türkiye to expand patient access to treatments with the OncoSil™ device.
Sydney, Australia – 15 August 2024:
Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce the successful surgical resection of a pancreatic tumor in the first patient commercially treated with the OncoSil™ device in Türkiye.
This significant milestone marks a promising development in the treatment of pancreatic cancer, demonstrating the effectiveness of the OncoSil™ device in combination with chemotherapy. The patient, who was initially diagnosed with unresectable locally advanced pancreatic cancer, underwent treatment with the OncoSil™ device, combined with chemotherapy. Following this combined treatment approach, the patient’s tumor was successfully reduced to a size and state that made it amenable to surgical resection.
The surgery was performed by Prof. Dr. Koray Acarli, a renowned specialist in pancreatic surgery. Prof. Dr. Koray Acarli, the surgeon who performed the resection, shared his perspective on this significant achievement: “The successful resection following OncoSil™ treatment is a testament to the device’s ability to enhance the efficacy of conventional therapies.
This breakthrough offers new hope for patients who were previously considered inoperable, and we are excited about the future possibilities this treatment combination holds.”
Prof. Dr. Cuneyt Turkmen, a leading Nuclear Medicine physician who administered the OncoSil™ treatment, also expressed his optimism about the future potential of the device: “The application of the OncoSil™ device in this patient has provided a new avenue for treatment, enabling the reduction of the tumor to a resectable state.
This case highlights the potential of OncoSil™ to transform the treatment landscape for patients with locally advanced pancreatic cancer.” OncoSil Medical CEO & Managing Director, Nigel Lange, said: “We are thrilled to see the positive outcome from the first use of the OncoSil™ device in Türkiye. This achievement underscores the global potential of OncoSil™ to improve the lives of patients battling pancreatic cancer. We look forward to advancing our clinical program and bringing this innovative treatment option to more patients worldwide.”
